TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02203773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
Study: NCT02262572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan /HCTZ - compression tablet (DC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan /HCTZ - dry granulation tablet (DG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan /HCTZ - present commercial formulation
Study: NCT01756586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Control
Study: NCT01700686

Intervention type: OTHER
Intervention: Meal test and dexa scan
Description: Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
Study: NCT04719208

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water (E) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (A) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (B) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betadine (C) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study: NCT01153659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: RAB ER 50 mg capsule once per day on Days 1-5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex (rabeprazole)
Description: Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
Study: NCT02134860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
Study: NCT02332174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rufinamide
Description: comparison of different doses, sex and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rufinamide
Description: comparison of different doses, sex and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rufinamide
Description: comparison of different doses, sex and medication conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rufinamide
Description: comparison of different doses, sex and medication conditions
Study: NCT03862183

Intervention type: OTHER
Intervention: continuing medical education program
Description: educating all the involved doctor the same medical knowledge on hypertension control

Intervention type: OTHER
Intervention: continuing medical education program
Description: educating all the involved doctor the same medical knowledge on hypertension control
Study: NCT01168726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies
Description: Personalized feedback on use of protective behavioral strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Personalized feedback on how one's own drinking compares to relevant norms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Education
Description: Educational information about harms associated with heavy drinking.
Study: NCT04664374

Intervention type: OTHER
Intervention: MyMood
Description: Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).

Intervention type: OTHER
Intervention: MyMood
Description: Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
Study: NCT03943641

Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on retrospective analysis of linked routinely-collected healthcare data
Study: NCT03738488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing + images
Description: To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Images
Description: To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
Study: NCT01787630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Injection in connection with ultrasound
Study: NCT02929030

Intervention type: DEVICE
Intervention: Nano
Description: The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
Study: NCT01126723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-Control
Description: The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
Study: NCT02677194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED
Description: There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.

Intervention type: OTHER
Group type: OTHER
Intervention: Control device
Description: Device without any LED exposition
Study: NCT04678297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity + emotion regulation intervention
Description: The intervention meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention will be led by certified instructors trained in working with back pain patients. The instructor leads participants through a series of physical activity exercises at a slow-moderate pace. Participants will be asked to practice every day for 20 minutes to maximize the benefit of the intervention. Participants also receive a home practice manual containing some basic, safe postures that can be performed on days they are not attending the formal in-person sessions.
Study: NCT03293030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab treatment
Study: NCT03584269

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTOT
Description: Long term oxygenatory tyherapy without NIV
Study: NCT00658281

Intervention type: PROCEDURE
Intervention: CBCT Scan
Description: Cone Beam Computed Tomography (CBCT) scan performed once a week.

Intervention type: PROCEDURE
Intervention: OBI KV Imaging
Description: On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
Study: NCT02089061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT04678297

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity control intervention
Description: The interventions meet twice weekly for 12 weeks, 1.25 hrs./session. This intervention is designed to require a similar amount of physical exertion. Classes involve conventional exercises appropriate for patients with CLBP, including a comprehensive set of exercises that stretch all the major muscle groups, with an emphasis on the trunk and legs. The intervention will include all 12 stretching exercises used in the exercise intervention of previous studies that have successfully used it in comparison to yoga, plus 3 additional stretches (hip internal rotators, hip adductors and hip flexion).Participants will be asked to practice every day for 20 minutes home as well. Printed handouts will be provided to facilitate home practice. In addition, a video demonstrating all the exercises will be provided to assist participants in practicing safely. Classes will be led by a licensed physical therapist who has previous experience leading exercise classes.
Study: NCT04172688

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose-enriched inulin
Description: Synergy1
Study: NCT00378014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basiliximab
Description: All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CNI
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Study: NCT04172688

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Description: Equicaloric dose of maltodextrin
Study: NCT01562275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: multiple doses
Study: NCT00378014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNI
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Study: NCT02965612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injex
Description: administration of Specific Immunotherapy (ITS) with car pressure injector without a needle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCIT
Description: administration of Specific Immunotherapy (ITS) via traditional subcutaneous
Study: NCT01562275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: multiple doses
Study: NCT03680781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta-burst stimulation (iTBS)
Description: Participants will receive iTBS to the left DLPFC or bilateral DLPFC, to the right and left DLPFC. The DLPFC will be targeted utilizing either Localite's neuronavigation system or Nexstim's eField neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC or bilateral DLPFC using either a MagVenture MagPro X100 or a Nexstim TMS device.
Study: NCT01153659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium (esomeprazole)
Description: Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
Study: NCT03722459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
Study: NCT01133366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin sodium
Description: 25 mg of warfarin oral (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium; warfarin sodium
Description: 200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
Study: NCT02392377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV or IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo esophagectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo esophagectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00807859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab
Description: AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 30 mg/kg, Capecitabine and Lapatinib
Description: AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 10 mgkg, Paclitaxel and Trastuzumab
Description: AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Description: AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Study: NCT00066859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft 50 mg
Description: Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: St. John's Wort 600 mg
Description: St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
Study: NCT01852786

Intervention type: OTHER
Intervention: Contraceptives, Oral, Combined
Description: • The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).

Intervention type: OTHER
Intervention: Controls
Description: The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
Study: NCT02659657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
Study: NCT04575233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted Transversus Abdominis Plane (TAP) block
Description: The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-assisted Transversus Abdominis Plane (TAP) block
Description: Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
Study: NCT00718627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Heterologous Liver Cells
Description: Multiple applications of liver cell suspension for infusion
Study: NCT03205839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based self-help intervention
Description: Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video.
Study: NCT01258010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
Study: NCT01977482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet for GSK1278863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: rhEPO will be procured from local market